Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13381316 | 1.00 | HSD17B10 (0.47) | HSD17B10ALDH1A1CHRM5CHRM3SMN1; SMN2 | |
| SCHEMBL10563724 | 0.98 | HSD17B10 (0.45) | HSD17B10ALDH1A1CHRM5CHRM3SMN1; SMN2 | |
| SCHEMBL24489899 | 0.94 | ALDH1A1 (0.46) | HSD17B10ALDH1A1CHRM5CHRM3SMN1; SMN2 | |
| SCHEMBL21764406 | 0.94 | ALDH1A1 (0.46) | HSD17B10ALDH1A1CHRM5CHRM3SMN1; SMN2 | |
| SCHEMBL21791334 | 0.92 | ATM (0.44) | HSD17B10ALDH1A1 | |
| SCHEMBL15199219 | 0.92 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2SIGMAR1NPC1 | |
| SCHEMBL13214851 | 0.91 | ALDH1A1 (0.46) | ALDH1A1CHRM5CHRM3SMN1; SMN2SIGMAR1 | |
| SCHEMBL25018192 | 0.91 | KDM4E (0.44) | HSD17B10ALDH1A1CHRM5CHRM3SMN1; SMN2 | |
| SCHEMBL24540412 | 0.89 | HSD17B10 (0.39) | HSD17B10ALDH1A1CHRM5CHRM3SMN1; SMN2 | |
| SCHEMBL12327463 | 0.89 | HSD17B10 (0.39) | HSD17B10ALDH1A1CHRM5CHRM3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4885363-A | RADIOPHARMACEUTICAL IMAGING; MEDICAL DIAGNOSIS | E. R. SQUIBB & SONS, INC. (US) | 1989-12-05 | — | — | US | claimed |
| EP-0292689-A2 | Substituted 1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclo-dodecane and analogs | BRACCO INTERNATIONAL B.V. (NL) | 1988-11-30 | — | — | EP | claimed |
| US-20240238458-A1 | COMPOUNDS TARGETING FIBROBLAST-ACTIVATION PROTEIN AND METHODS OF USE THEREOF | PURDUE RESEARCH FOUNDATION | 2024-07-18 | — | — | US | disclosed |
| US-20240207458-A1 | TARGETED ALPHA PARTICLE THERAPY FOR SOMATOSTATIN RECEPTOR 2 POSITIVE NEUROENDOCRINE TUMORS AND METASTASES | WAKE FOREST UNIVERSITY | 2024-06-27 | — | — | US | disclosed |
| WO-2023239829-A2 | SYSTEMS AND METHODS FOR ASSESSING DISEASE BURDEN AND PROGRESSION | PROGENICS PHARMACEUTICALS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-11793895-B2 | Residualizing linkers and uses thereof | CENTRE FOR PROBE DEVELOPMENT AND COMMERCIALIZATION | 2023-10-24 | — | — | US | disclosed |
| US-20230321285-A1 | METHOD OF TREATING PSMA-EXPRESSING CANCERS | NOVARTIS AG (CH) | 2023-10-12 | — | — | US | disclosed |
| US-20230302164-A1 | PSMA-Targeting Ligands With Optimal Properties for Imaging and Therapy | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2023-09-28 | — | — | US | disclosed |
| US-20230173112-A1 | PSMA-Targeting Ligands With Optimal Properties for Imaging and Therapy | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2023-06-08 | — | — | US | disclosed |
| US-20230165981-A1 | [161Tb]-BASED RADIOPEPTIDES | UNIVERSITÄT BASEL (CH) | 2023-06-01 | — | — | US | disclosed |
| US-20230098279-A1 | METHOD OF TREATING PSMA-EXPRESSING CANCERS | ENDOCYTE, INC. | 2023-03-30 | — | — | US | disclosed |
| US-7321045-B2 | Vitronectin receptor antagonist pharmaceuticals | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-01-22 | — | — | US | disclosed |
| WO-2005048810-A2 | SIGMA-2 RECEPTOR RADIOTRACERS FOR IMAGING THE PROLIFERATIVE STATUS OF SOLID TUMORS | WASHINGTON UNIVERSITY IN ST. LOUIS (US) | 2005-06-02 | — | — | WO | disclosed |
| US-6143274-A | IMAGING MAMMALIAN TISSUE UTILIZING A NON-IONIC COMPLEX OF A PARAMAGNETIC ION OF LANTHANIDE ELEMENT AND A MACROCYCLIC CHELATING AGENT | BRACCO DIAGNOSTICS, INC. | 2000-11-07 | — | — | US | disclosed |
| US-5846519-A | Method for imaging mammalian tissue using 1-substituted-1,4,7-tricarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs | BRACCO DIAGNOSTICS INC. (US) | 1998-12-08 | — | — | US | disclosed |
| US-5674470-A | Method for imaging mammalian tissue using 1-substituted- 4,7,10-tricarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs | BRACCO DIAGNOSTICS INC. (US) | 1997-10-07 | — | — | US | disclosed |
| EP-0292689-B1 | Substituted 1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclo-dodecane and analogs | BRACCO INT BV (NL) | 1996-07-31 | — | — | EP | disclosed |
| US-5474756-A | Chelate compound of a paramagnetic ion of lanthanide element | BRACCO INTERNATIONAL B.V. (NL) | 1995-12-12 | — | — | US | disclosed |
| US-4885363-A | RADIOPHARMACEUTICAL IMAGING; MEDICAL DIAGNOSIS | E. R. SQUIBB & SONS, INC. (US) | 1989-12-05 | — | — | US | disclosed |
| EP-0292689-A2 | Substituted 1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclo-dodecane and analogs | BRACCO INTERNATIONAL B.V. (NL) | 1988-11-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230173112-A1 | PSMA-Targeting Ligands With Optimal Properties for Imaging and Therapy | PSMA1, PSMA2, FOLH1 | HSD17B10 4201/4885ALDH1A1 1627/4885CHRM5 3664/4885 |
| US-20230321285-A1 | METHOD OF TREATING PSMA-EXPRESSING CANCERS | IL15RA, IL15, CD274 | HSD17B10 2970/4885ALDH1A1 818/4885CHRM5 2466/4885 |
| US-20230098279-A1 | METHOD OF TREATING PSMA-EXPRESSING CANCERS | IL15RA, IL15, CD274 | HSD17B10 3452/4885ALDH1A1 1201/4885CHRM5 2471/4885 |
| US-20240238458-A1 | COMPOUNDS TARGETING FIBROBLAST-ACTIVATION PROTEIN AND METHODS OF USE THEREOF | FAP, FIBP, FGFR1 | HSD17B10 3923/4885ALDH1A1 2246/4885CHRM5 4855/4885 |
| US-20230165981-A1 | [161Tb]-BASED RADIOPEPTIDES | SSTR1, SSTR4, SSTR3 | HSD17B10 4233/4885ALDH1A1 4707/4885CHRM5 4546/4885 |
| US-20240207458-A1 | TARGETED ALPHA PARTICLE THERAPY FOR SOMATOSTATIN RECEPTOR 2 POSITIVE NEUROENDOCRINE TUMORS AND METASTASES | SSTR2, SSTR1, SSTR5 | HSD17B10 4476/4885ALDH1A1 4724/4885CHRM5 1831/4885 |
| US-11793895-B2 | Residualizing linkers and uses thereof | CD44, CD47, MTCL3 | HSD17B10 1339/4885ALDH1A1 619/4885CHRM5 3233/4885 |
| US-20230302164-A1 | PSMA-Targeting Ligands With Optimal Properties for Imaging and Therapy | PSMA1, PSMA2, FOLH1 | HSD17B10 4215/4885ALDH1A1 1479/4885CHRM5 3396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.